Camrelizumab Combined With Apatinib Mesylate

NCT05380986 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

500

Enrollment

OTHER_GOV

Sponsor class

Conditions

Solid Tumor

Interventions

DRUG: Camrelizumab combined with apatinib mesylate

Sponsor

Henan Cancer Hospital